Matica Biotechnology, a U.S. affiliate of CHA Biotech, said that the company has dedicated its contract development manufacturing organization (CDMO) facility for cell and gene therapy.

Located in College Station, Texas, Matica’s new CDMO manufacturing facility has a 500L bioreactor and meets the FDA's current good manufacturing practice (cGMP) standard.

As the CDMO business of cell and gene therapy requires advanced technology and expertise, Matica has successfully secured the top-tier cell and gene therapy manufacturing experts from various global CDMO players, such as Lonza, Fujifilm Dyosynth, and Charles River.

Matica also installed a modular POD (Portable on Demand) system, which provides the flexibility to adjust resources required depending on client needs and product requirements.

To keep pace with accelerated clinical development time frames, production complexities, and demand, Matica already has two collaborations at the new facility.

The company is working with Sartorius to develop and optimize advanced viral vector manufacturing technologies for large-scale vector production. It also partners with Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing for plasmid DNA and protein studies to speed up biotech R&D and commercial manufacturing.

“Compared to small molecule or protein-based products, cell and gene therapy is the next generation medicine that requires application of innovative technology.” Matica CEO Song Yun-jeong said. “By applying the 20 years of cell therapy research history by CHA Biotech, Matica’s goal is to become the industry’s leading CDMO with a specialty in cell and gene therapies.”